July 27 (Reuters) – AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President Donald Trump’s “most-favoured-nation” policy seeking lower drug prices for Americans, a senior company executive said on Monday.
“Our pricing approach across all of launches now has really evolved in response to MFN,” David Fredrickson, AstraZeneca’s executive vice president for the oncology business, told investors.
(Reporting by Pushkala Aripaka, Raechel Thankam Job in Bengaluru; Editing by Arun Koyyur)
Comments